MX2022016342A - Union de anticuerpos multiespecificos a bcma. - Google Patents

Union de anticuerpos multiespecificos a bcma.

Info

Publication number
MX2022016342A
MX2022016342A MX2022016342A MX2022016342A MX2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A MX 2022016342 A MX2022016342 A MX 2022016342A
Authority
MX
Mexico
Prior art keywords
bcma
specific antibodies
antibodies binding
antibodies
sup
Prior art date
Application number
MX2022016342A
Other languages
English (en)
Inventor
Ute Schellenberger
Nathan Trinklein
Katherine Harris
Omid Vafa
Aldred Shelley Force
Harbani Malik
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2022016342A publication Critical patent/MX2022016342A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Se dan a conocer anticuerpos multiespecíficos de cadena pesada humana (por ejemplo, UniAbsTM) que se unen a BCMA, junto con métodos para preparar tales anticuerpos, composiciones, incluyendo composiciones farmacéuticas, que comprenden tales anticuerpos y su uso para tratar trastornos que se caracterizan por la expresión de BCMA.
MX2022016342A 2020-06-30 2021-06-30 Union de anticuerpos multiespecificos a bcma. MX2022016342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046477P 2020-06-30 2020-06-30
PCT/US2021/039961 WO2022006316A1 (en) 2020-06-30 2021-06-30 Multi-specific antibodies binding to bcma

Publications (1)

Publication Number Publication Date
MX2022016342A true MX2022016342A (es) 2023-01-24

Family

ID=77127069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016342A MX2022016342A (es) 2020-06-30 2021-06-30 Union de anticuerpos multiespecificos a bcma.

Country Status (15)

Country Link
US (1) US20230257473A1 (es)
EP (1) EP4171750A1 (es)
JP (1) JP2023532129A (es)
KR (1) KR20230038211A (es)
CN (1) CN116472049A (es)
AU (1) AU2021300179A1 (es)
BR (1) BR112022027101A2 (es)
CA (1) CA3189297A1 (es)
CL (1) CL2022003754A1 (es)
CO (1) CO2023000808A2 (es)
CR (1) CR20220656A (es)
IL (1) IL299027A (es)
MX (1) MX2022016342A (es)
PE (1) PE20230464A1 (es)
WO (1) WO2022006316A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR101151957B1 (ko) 2004-07-22 2012-06-01 로저 킹돈 크레이그 결합 분자
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
NZ612647A (en) 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CA2995754A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
KR20190052006A (ko) 2016-08-24 2019-05-15 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
JP7030109B2 (ja) 2016-09-14 2022-03-04 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
JP2020525408A (ja) 2017-06-09 2020-08-27 ジェモアブ モノクローナルズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＧＥＭｏａＢ Ｍｏｎｏｃｌｏｎａｌｓ ＧｍｂＨ 共通キメラ抗原受容体発現免疫細胞のためのターゲティングモジュールならびに癌、感染および自己免疫障害の処置における使用
EP3642236A1 (en) * 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
EP3642237A2 (en) * 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CA3068444A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-b-cell maturation antigen chimeric antigen receptors with human domains

Also Published As

Publication number Publication date
CR20220656A (es) 2023-03-01
BR112022027101A2 (pt) 2023-03-14
WO2022006316A1 (en) 2022-01-06
KR20230038211A (ko) 2023-03-17
JP2023532129A (ja) 2023-07-26
CL2022003754A1 (es) 2023-07-07
CO2023000808A2 (es) 2023-02-16
PE20230464A1 (es) 2023-03-14
CA3189297A1 (en) 2022-01-06
EP4171750A1 (en) 2023-05-03
US20230257473A1 (en) 2023-08-17
IL299027A (en) 2023-02-01
AU2021300179A1 (en) 2023-02-02
CN116472049A (zh) 2023-07-21

Similar Documents

Publication Publication Date Title
JOP20210253A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
MX2022016342A (es) Union de anticuerpos multiespecificos a bcma.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
CR20200322A (es) Anticuerpos de cadena pesada que se unen a cd22
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
CR20230149A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539)
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EP4183806A3 (en) Glycan-interacting compounds and methods of use
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
CR20230507A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
MX2023005693A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa.
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
MX2023012181A (es) Anticuerpos anti-cd20 y estructuras car-t.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.